首页> 美国卫生研究院文献>Asian Journal of Andrology >Investigating intratumour heterogeneity by single-cell sequencing
【2h】

Investigating intratumour heterogeneity by single-cell sequencing

机译:通过单细胞测序研究肿瘤内异质性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intratumour heterogeneity is a longstanding field of focus for both researchers and clinicians. It refers to the diversity amongst cells within the same tumour. Two major hypotheses have attempted to explain the existence of intratumour heterogeneity: (i) the clonal evolution (CE) theory and (ii) the cancer stem cell (CSC) model. CE theory emphasizes the evolutionary biological characteristics of the tumour, underscoring the initiation and progression of the disease. In contrast, the CSC model focuses on stem cell differentiation into distinct functions in order to stabilize the tumour microenvironment. Here we consider single-cell sequencing (SCS) as a newly developed technique for application to the investigation of intratumour heterogeneity and assess its relevance within research and clinical environments. Early detection of rare tumour cells, monitoring of circulating tumour cells (CTCs) and control of the occurrence of drug resistance are important goals in early diagnosis, prognosis prediction and individualized medicine.
机译:肿瘤内异质性是研究人员和临床医生长期关注的领域。它指的是同一肿瘤内细胞之间的多样性。两种主要假设试图解释肿瘤内异质性的存在:(i)克隆进化(CE)理论和(ii)癌症干细胞(CSC)模型。 CE理论强调了肿瘤的进化生物学特征,强调了疾病的发生和发展。相反,CSC模型着重于将干细胞分化为不同的功能,以稳定肿瘤的微环境。在这里,我们将单细胞测序(SCS)作为一种新开发的技术,用于研究肿瘤内异质性并评估其在研究和临床环境中的相关性。早期发现稀有肿瘤细胞,监测循环肿瘤细胞(CTC)并控制耐药性的发生是早期诊断,预后预测和个性化药物的重要目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号